Product Development

Back to School 2020: The imperative of COVID-19 — biopharma’s once-in-a-generation chance for change 

BioCentury’s 28th Annual Back to School calls on biopharma to convert its COVID response to a new era of efficient drug development and address the urgent healthcare chasms exposed by the crisis.

BioCentury calls on industry to convert its COVID response to a new era of efficient drug development and address the urgent healthcare chasms exposed by the crisis

Biopharmas must address the reality of racial disparities in health outcomes exposed by COVID-19 

COVID-19 shows why biopharmas need to build racial equity into their drug development mindset.

COVID-19 shows why biopharmas need to build racial equity into their drug development mindset

Having touched the third rail of data sharing in the pandemic, drug developers should hold on tight

COVID-19 has lit a path to greater data sharing.

COVID-19 has lit a path to greater data sharing

Master protocols should not be a one-off phenomenon confined to COVID-19

COVID-19 gives a master lesson in platform trials.

COVID-19 gives a master lesson in platform trials

Governments must work alongside industry to fill the cracks exposed by COVID-19 before the next, inevitable, pandemic

Public sector leaders must step forward to prepare for future pandemics by improving surveillance, investing in countermeasures R&D, creating markets for antibiotics, and building surge capacity for manufacturing and diagnostics.

When next crisis hits, the world should be able to turn to a stockpile of countermeasures and an efficient system for manufacturing, distributing them

Letter from the Editor: Back to School 2020

Back to School this year carries a unique irony, given that many students aren’t going back to school in any normal format. Since its launch in 1993, Back to School has been published at Labor


<div class="articleContainer">
<div class="articleWrapper">
<div class="articleContent">
<h1 class="text title" doc-editable="text" data-component-id="doc-1ef7l320d0">Biopharmas must address the reality of racial disparities in health outcomes exposed by COVID-19<span style="white-space: pre;"> </span></h1><h2 class="title-bottom" doc-editable="title" data-component-id="doc-1ehqjp2q80">COVID-19 shows why biopharmas need to build racial equity into their drug development mindset</h2><div class="byline ng-tns-c17-4 ng-star-inserted" data-component-id="doc-1ef7l3fol0">
    <span class="ng-tns-c17-4" doc-editable="text">By C. simone fishburn, editor in chief, and Steve Usdin, Washington Editor</span>
</div><div class="date" data-component-id="doc-1ef7l3l440">
  <span class="byline" doc-editable="text"></span>
</div></div></div></div>


<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>

Paywall Not Entitled Title

Request a Trial

Purchase This Article

<center><span style="font-weight:300;">[Log in]{{login}}</span></center>

Paywall Sub log in

!function(e,i,n,s){var t="InfogramEmbeds",d=e.getElementsByTagName("script")[0];if(window[t]&&window[t].initialized)window[t].process&&window[t].process();else if(!e.getElementById(n)){var o=e.createElement("script");o.async=1,o.id=n,o.src="https://e.infogram.com/js/dist/embed-loader-min.js",d.parentNode.insertBefore(o,d)}}(document,0,"infogram-async");